Rifampicin

( DrugBank: Rifampicin / KEGG DRUG: Rifampin )

6 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
17	Multiple system atrophy	1
46	Malignant rheumatoid arthritis	1

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	2
299	Cystic fibrosis	4
338	Progressive familial intrahepatic cholestasis	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04070495 (ClinicalTrials.gov)	August 27, 2019	26/8/2019	A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin	A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin(A Drug Interaction Study With a ...	Parkinson's Disease	Drug: KW-6356;Drug: Clarithromycin;Drug: Rifampicin	Kyowa Kirin Co., Ltd.	NULL	Completed	20 Years	44 Years	Male	20	Phase 1	Japan

First Previous1Next Last

17. Multiple system atrophy

Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01287221 (ClinicalTrials.gov)	March 2011	28/1/2011	Study of Rifampicin in Multiple System Atrophy	Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy	Multiple System Atrophy	Drug: Rifampicin;Drug: placebo	Phillip Low	National Institute of Neurological Disorders and Stroke (NINDS);Vanderbilt University;Rare Disease R ...	Terminated	30 Years	80 Years	All	100	Phase 3	United States

First Previous1Next Last

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01336218 (ClinicalTrials.gov)	April 2011	14/4/2011	Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.	An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinet ...	Rheumatoid Arthritis;Healthy Volunteers	Drug: fostamatinib;Drug: rifampicin	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	15	Phase 1	United States

First Previous1Next Last

93. Primary biliary cholangitis

Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004011-44-GB (EUCTR)	10/08/2020	28/05/2020	Trial of URsodeoxycholic acid versus RIFampicinin severe early onset Intrahepatic Cholestasis of pre ...	A randomised trial of URsodeoxycholic acid versus RIFampicinin severe early onset Intrahepatic Chole ...	Intrahepatic Cholestasis of Pregnancy (ICP) is an serious liver condition in pregnancy. The main sym ...	Product Name: Rifampicin INN or Proposed INN: Rifampicin Product Name: Ursodeoxycholic acid INN or Prop ...	The University Of Adelaide	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	108	Phase 3	Finland;Australia;Netherlands;United Kingdom;Sweden
2	EUCTR2018-004011-44-FI (EUCTR)	20/05/2020	26/09/2019	Trial of URsodeoxycholic acid versus RIFampicinin severe early onset Intrahepatic Cholestasis of pre ...	A randomised trial of URsodeoxycholic acid versus RIFampicinin severe early onset Intrahepatic Chole ...	Intrahepatic Cholestasis of Pregnancy (ICP) is an serious liver condition in pregnancy. The main sym ...	Product Name: Rifampicin Product Name: Ursodeoxycholic acid	The University of Adelaide	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	108	Phase 4	Finland;Australia;Netherlands;United Kingdom;Sweden

First Previous1Next Last

299. Cystic fibrosis

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003501-10-NO (EUCTR)	08/03/2021	29/05/2020	Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with ...	Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with ...	Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Amoxicillin Product Name: Amoxicillin INN or Proposed INN: AMOXICILLIN Trade Name: Amoxicil ...	Vãstre Gõtalandsregionen, Sweden	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	100	Phase 4	Denmark;Norway;Sweden
2	EUCTR2019-003501-10-DK (EUCTR)	22/01/2021	22/04/2020	Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with ...	Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with ...	Cystic fibrosis MedDRA version: 22.1;Level: LLT;Classification code 10068288;Term: Cystic fibrosis p ...	INN or Proposed INN: AMOXICILLIN INN or Proposed INN: CLAVULANIC ACID INN or Proposed INN: AMOXICILLIN ...	Västra Götalandsregionen	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	100	Phase 4	Denmark;Norway;Sweden
3	EUCTR2019-003501-10-SE (EUCTR)	08/04/2020	07/04/2020	Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with ...	Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with ...	Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	INN or Proposed INN: AMOXICILLIN INN or Proposed INN: CLAVULANIC ACID INN or Proposed INN: AMOXICILLIN ...	Västra Götalandsregionen	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	100	Phase 4	Denmark;Norway;Sweden
4	EUCTR2013-000219-25-IT (EUCTR)	18/07/2013	12/04/2018	MRSA study.	Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter stu ...	Patients affected by cystic fibrosis and who present an initial infection of MRSA.;Therapeutic area: ...	Product Name: Rifampin INN or Proposed INN: RIFAMPICIN Product Name: Trimethoprim-sulfamethoxazole INN ...	AOU Meyer	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	100	Phase 3	Italy

First Previous1Next Last

338. Progressive familial intrahepatic cholestasis

Clinical trials : 60 / Drugs : 26 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 2

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000017823	2013/07/17	05/06/2015	A study to assess the safety and efficacy of rifampicinfor progressive familial intrahepatic cholest ...	A study to assess the safety and efficacy of rifampicinfor progressive familial intrahepatic cholest ...	Progressive familial intrahepatic cholestasisBenign recurrent intrahepatic cholestasis	Rifampicin(RFP, 10 mg/kg/day) are given for 4-8 weeks. When RFP is effective against cholestasis, RFP ...	Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University	NULL	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	3	Not selected	Japan

First Previous1Next Last